OTLK - Apellis Trial Progress And Other News: The Good Bad And Ugly Of Biopharma
Apellis Reports Completion of Enrollment for Two Phase 3 Studies
Apellis Pharmaceuticals Inc. (APLS) reported that it has completed enrollment for two of its Phase 3 studies which are DERBY and OAKS. Both the studies are designed to evaluate intravitreal pegcetacoplan for treating geographic atrophy (GA) secondary to age-related macular degeneration. There is currently no approved therapy for treating geographic atrophy.
Apellis has enrolled 1,259 patients across both the studies with 621 patients in DERBY study while OAKS has 638 patients in it. Federico Grossi, M.D., Ph.D., Chief Medical Officer of